GLP-1 weight loss: how much muscle are you losing?
Dr. Farrukh SheikhGLP-1 medicines such as Wegovy and Mounjaro can produce dramatic weight loss — but not everything you lose is fat. New research is shifting attention from how much weight people lose to what that lost weight actually consists of.
In 30 Seconds
A 2026 meta-analysis found that around 35.2% of the weight lost with semaglutide was lean mass. With tirzepatide, the figure was about 25.4%.
In the new COURAGE trial, people receiving semaglutide alone lost 7.3% of their DXA-measured lean mass over 52 weeks.
An experimental add-on treatment preserved roughly 70% of thigh-muscle loss in an MRI substudy — a sign that researchers are now trying to improve the quality of GLP-1 weight loss, not simply increase the amount lost.
Get the full article in your inbox
Receive the full GLP-1 muscle article as a PDF and stay up to date with important new health research, medical developments and scientific discoveries — explained clearly, compassionately and without the hype.
What the News Is Saying
A new question is beginning to shape the future of obesity treatment.
Until recently, the headline was simple: how much weight can these medicines help people lose?
Now the question is becoming more sophisticated: what kind of weight is being lost?
On 1 October 2026, Regeneron reported Phase 2 COURAGE trial results showing that its experimental drug trevogrumab, used alongside semaglutide, helped preserve a substantial amount of lean mass and muscle during weight loss.
In an MRI substudy, the add-on treatment preserved roughly 70% of thigh-muscle loss.
That matters because the obesity-treatment race may be shifting from simply achieving more weight loss towards achieving better-quality weight loss.
The number on the scale hides something important
The bathroom scale tells you that your total body weight has gone down.
It does not tell you what that weight consisted of.
When somebody loses a substantial amount of weight, the loss can come from a mixture of:
- fat mass
- lean mass
- water and glycogen changes
- and, depending on the circumstances, some skeletal muscle
This means two people can both lose 15 kg while experiencing quite different changes in body composition.
Fat mass
This is the body fat you are carrying.
Lean mass
Lean mass generally refers to everything that is not fat — including muscle, organs, body water and other non-fat tissues.
Muscle
This refers specifically to skeletal muscle, the tissue most people mean when they talk about strength, tone and physical function.
Lean mass and muscle are therefore not the same thing. A study reporting loss of lean mass does not automatically mean the same amount of skeletal muscle has been lost.
The numbers are bigger than many people realise
A 2026 meta-analysis estimated that lean mass accounted for approximately:
- 35.2% of total weight lost with semaglutide
- 25.4% with tirzepatide
- 26.8% with liraglutide
- 26.2% with lifestyle weight loss
- 17.5% with lifestyle weight loss plus resistance training
What the evidence is telling us
What was studied: Changes in body composition during incretin-based and lifestyle weight loss.
Main finding: Substantial weight loss can include meaningful lean-mass loss, but the proportion varies between approaches. Lifestyle weight loss combined with resistance training showed the lowest lean-mass share in this comparison.
Why it matters: The number on the scale cannot tell you whether weight loss is coming mainly from fat or whether a significant amount of lean tissue is being lost as well.
Published Human Evidence
COURAGE Phase 2
In the 2026 COURAGE trial, participants receiving semaglutide alone lost 7.3% of their DXA-measured lean mass over 52 weeks. In an MRI substudy, adding trevogrumab preserved roughly 70% of thigh-muscle loss.
Why losing muscle matters
This is not simply a cosmetic issue.
Muscle contributes to:
- strength
- physical function
- balance and mobility
- recovery from illness
- metabolic health
- healthy ageing
For some people, modest lean-mass loss during successful weight loss may not translate into any major real-world problem.
For others, it could matter considerably — particularly people who are older, less active, already weak, recovering from illness, eating poorly or trying to prevent frailty and loss of independence.
You can become lighter on the scale without necessarily becoming stronger or healthier in everyday life.
What does this mean for me?
If you are losing weight on a GLP-1 medicine, the goal should not simply be to make the scale fall as quickly as possible.
You also want to protect:
- strength
- mobility
- day-to-day function
- adequate nutrition
- as much muscle as reasonably possible
That means paying attention to how you eat, how active you are and whether you are doing any strength-based exercise.
Who could be most affected?
Extra attention may be sensible for:
- older adults
- people with low baseline muscle or low lean-mass reserves
- people with sarcopenic obesity
- people with type 2 diabetes
- people losing weight very quickly
- people whose appetite suppression means they are eating very little
- people doing little or no resistance exercise
- people recovering from illness, inactivity or deconditioning
These groups are not proof of harm. They are simply situations in which muscle and nutritional reserve may deserve closer attention.
What can you do?
Resistance exercise
The strongest practical signal at present is resistance exercise.
In the 2026 meta-analysis, lifestyle weight loss combined with resistance training had the lowest proportion of lean mass in the weight lost: approximately 17.5%.
That does not prove resistance training completely prevents muscle loss, but it suggests that strength-based exercise may help shift weight loss towards a more favourable body-composition pattern.
Pay deliberate attention to protein
If you are losing weight rapidly, eating less and trying to preserve muscle, protein intake matters.
The difficulty is that there is no single protein target suitable for everybody. Requirements can vary with:
- age
- body size
- sex
- kidney health
- physical activity
- underlying health conditions
- rate of weight loss
The safer general principle is this:
people using GLP-1 medicines should pay deliberate attention to protein intake rather than assuming reduced appetite will automatically produce a nutritionally adequate diet.
Think beyond the scale
Changes in strength, mobility and everyday function may sometimes tell you more than body weight alone.
Difficulty with stairs, carrying shopping, rising from a chair, walking pace or exercise performance may be worth noticing — particularly if these change while weight is falling rapidly.
If you have stopped a GLP-1
The issue does not necessarily end when treatment stops.
The post-GLP-1 phase can involve:
- appetite returning strongly
- concerns about weight regain
- uncertainty about eating without the medication
- low confidence around exercise
- worries about rebuilding or preserving strength
That can create two simultaneous goals: protecting against weight regain and protecting or rebuilding strength.
Those goals are related, but they are not identical.
The catch: what we still do not know
- the long-term functional consequences of these body-composition changes
- how much measured lean-mass loss represents true skeletal-muscle loss
- which patients are most vulnerable
- how much resistance exercise and nutrition can offset the effect in real-world settings
- whether newer muscle-preserving drugs will prove safe, effective and widely useful
This is therefore a genuine issue, but not a fully settled one.
That is why it deserves calm, evidence-led discussion rather than alarmist oversimplification.
Five questions worth asking yourself
-
Am I losing weight very quickly?
Rapid loss may deserve closer attention to nutrition, strength and body composition. -
Am I eating enough protein and enough food overall?
Strong appetite suppression can sometimes make adequate nutrition surprisingly difficult. -
Am I doing any resistance or strength exercise?
This may be one of the most practical ways of helping preserve lean tissue during weight loss. -
Am I getting weaker?
Changes in stairs, carrying shopping, getting up from a chair, walking pace or exercise performance may matter more than another number on the scale. -
Do I need individual advice?
Older adults and people with frailty, diabetes, kidney disease, very low food intake or substantial weight loss may particularly benefit from personalised guidance.
Reader Takeaway
GLP-1 medicines can help many people lose substantial amounts of weight.
But some of that loss can be lean tissue, and part of the concern is whether skeletal muscle and physical function are also being affected.
The aim should increasingly be not merely more weight loss, but better-quality weight loss — losing fat while preserving as much strength and useful tissue as reasonably possible.
The scale tells you how much you lost. It does not tell you what you lost.
Updates to This Story
5 October 2026 — Article updated to reflect the latest available COURAGE evidence and current research on lean-mass preservation during GLP-1 treatment.
Sources & Further Reading
- Regeneron: Phase 2 COURAGE trial results, 1 October 2026
- 2026 meta-analysis comparing incretin therapies and lifestyle weight loss
- SURMOUNT-1 body-composition substudy
- 2026 systematic review and meta-analysis on GLP-1 treatment and body composition
- Review of lean-mass and musculoskeletal preservation during GLP-1 treatment
Health Note
This article is for general information and discussion. It does not diagnose, prescribe or replace personalised medical advice.
Decisions about GLP-1 medicines, diet, exercise, protein intake or health conditions should be considered in the context of the individual, especially where there is frailty, kidney disease, diabetes, major illness or other medical complexity.